Table 1.
Summary of Seven Phase III Randomized Controlled Trials That Investigated GLP-1 Receptor Agonists and Weight Loss.
| Study | GLP-1 Intervention | Lifestyle Intervention | Duration (Weeks) | No. of Participants | Percent Change in Body Weight | ||
|---|---|---|---|---|---|---|---|
| Placebo | GLP-1 | Placebo | GLP-1 | ||||
| Wilding 2021 | Semaglutide 2.4 mg per week | Counseling sessions every 4 weeks to encourage a reduced-calorie diet and increased physical activity. | 68 | 655 | 1306 | −2.6 (−2.4) | −15 (−15) |
| Wadden 2021 | Semaglutide 2.4 mg per week | Low-calorie diet for the first 8 weeks and intensive behavioral therapy (ie, 30 counseling visits). | 68 | 204 | 407 | −6.2 (−5.7) | −17 (−16) |
| Pi-Sunyer 2015 | Liraglutide 3.0 mg per day | Counseling on lifestyle modification. | 56 | 1225 | 2437 | −2.8 (−2.6) | −8.4 (−8.0) |
| le Roux 2017 | Liraglutide 3.0 mg per day | Counseling on lifestyle modification. | 160 | 738 | 1472 | −2.0 (−1.9) | −6.5 (−6.1) |
| Blackman 2016 | Liraglutide 3.0 mg per day | Counseling on diet and physical activity. Daily energy intake of 500 kcal. At least 150 min of physical activity/week. | 32 | 178 | 175 | −1.9 (−1.6) | −6.7 (−5.7) |
| Kim 2013 | Liraglutide 1.8 mg per day | Advised to decrease calorie intake by 500 kcal/day. | 14 | 27 | 24 | −3.3 (−3.7) | −6.8 (−7.7) |
| Jastreboff 2022 | Tirzepatide 5 mg per week | Counseling on diet and physical activity. Advised to decrease calorie intake by 500 kcal/day. At least 150 min of physical activity/week. | 72 | 643 | 630 for 5 mg group | −3.2 (−3.1) | −15 (−15) for 5 mg group |
| Tirzepatide 10 mg per week | 636 for 10 mg group | −21 (−20) for 10 mg group | |||||
| Tirzepatide 15 mg per week | 630 for 15 mg group | −22 (−21) for 15 mg group | |||||
Abbreviations: GLP-1: Glucagon-like peptide-1; mg: milligram; No.: number.